{"name": "lonapegsomatropin", "category": "drug", "content": "Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin. Lonapegsomatropin was approved for medical use in the United States in August 2021, and in the European Union in January 2022.   == Medical uses == Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.   == History == The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.   == References ==   == Further reading ==   == External links == Clinical trial number NCT02781727 for \"A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)\" at ClinicalTrials.gov"}